Table 2.

Adjusted HRs for treatment discontinuation due to specific reasons with each agent, in comparison to TNFi

Variable	Reference	HR (95% CI)
	TNFi (n=3577)	aIL-6R (n=1497)	CTLA4-Ig (n=1139)	JAKi (n=453)
Ineffectiveness	1	0.52 (0.46 to 0.61)***	0.74 (0.64 to 0.84)***	0.67 (0.54 to 0.83)***
Toxic adverse events	1	0.99 (0.85 to 1.17)	0.78 (0.64 to 0.95)*	0.88 (0.65 to 1.20)
Non-toxic reasons	1	0.97 (0.82 to 1.18)	1.20 (1.00 to 1.44)*	0.93 (0.66 to 1.32)
Remission	1	0.87 (0.65 to 1.17)	0.66 (0.45 to 0.98)*	1.12 (0.58 to 2.16)
Total discontinuation (excluding non-toxic reasons and remission)	1	0.66 (0.60 to 0.73)***	0.75 (0.67 to 0.84)***	0.73 (0.62 to 0.87)***

Differences between drugs were assessed using the Cox p value.

*p<0.05, ***p<0.001.

aIL-6R, anti-interleukin-6 receptor antibodies; CTLA4-Ig, cytotoxic T lymphocyte-associated antigen-4-Ig; JAKi, Janus kinase inhibitors; TNFi, tumour necrosis factor inhibitors.